HSPTU has consummated its business combination with SL Bio, transforming from a SPAC searching for targets into a subsidiary of a new public company (PubCo) with dramatically deteriorated financial position.
This represents the completion of HSPTU's SPAC lifecycle, where shareholders now own shares of PubCo rather than the original SPAC entity. The company has moved past its November 2025 deadline pressure and achieved its primary objective of completing a business combination, but investors should closely monitor the new combined entity's performance on Nasdaq.
The financial statements show severe deterioration with stockholders' equity plunging from $451K to negative $1.3M (-393%), while current assets collapsed 96% from $720K to just $30K and liabilities quintupled to $1.3M. Despite reporting higher net income of $1.8M, operating cash flow worsened significantly to negative $1.0M, and the balance sheet transformation suggests substantial transaction costs and a highly leveraged capital structure that raises immediate liquidity concerns for the post-combination entity.
Net income grew 1166.1% — bottom-line growth signals improving overall business health.
Operating cash flow fell 840.4% — earnings quality concerns; investigate working capital changes and non-cash items.
Liabilities grew 400.9% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 400.9% — significant near-term obligations; verify ability to meet short-term debt.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 95.9% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →